Home | News | Find a Doctor | Ask a Question | Free

Hair multiplication


#1

What is the latest on hair multiplication?


#2

» What is the latest on hair multiplication?

Your screen name…only spelled differently


#3

This is from the Intercytex Site … Anderans is working on this also, but we are not sure how far along they are…Follica is another promising research company…they are using a different method than multiplication

ICX-TRC - hair regeneration
ICX-TRC is an autologous hair regeneration therapy, a suspension of human dermal papilla cells, intended for the treatment of male pattern baldness and female diffuse alopecia.

It is intended that ICX-TRC will be used by specialists in hair transplant centres, dermatologists and plastic surgeons to treat patients with hair thinning or hair loss.

Background

Both male pattern baldness and female diffuse alopecia result in hair-loss or slowing of hair growth. They may be caused by physical damage to the hair itself or to the hair follicles, but commonly arise as a consequence of changes in the natural growth cycle of hair generally resulting in fewer dermal papilla cells. Approximately 95% of all cases are of genetic origin.

Market opportunity

Hair loss affects approximately 40% of men and 20% of women aged 50 and over. In the US there are an estimated 40 million men and 12 million women suffering from some degree of baldness. The estimated market size for hair regeneration products and treatments is over $1 billion for both men and women but only 2% of patients suffering hair loss currently seek any treatment indicating a potentially far higher market size*.

Existing conventional treatments, involving the transplant of whole hairs, represent the only means of regenerating bald or thinning areas. This is a highly costly ($10,000 - $20,000) specialist procedure. Extensive tissue is required, obtained by the removal of a large section of scalp leaving a significant scar at the donor site. Individual follicles are removed from the dissected scalp by specialised technicians and then individually re-implanted into surgical incisions created in the scalp. This procedure usually takes place during two, eight-hour implant sessions performed under a local anaesthetic. A lengthy recovery period may be required during which time the patient may suffer from pain, bleeding and swelling of the scalp. In general the cosmetic effect is excellent, however in all cases, the quality of outcome is limited by the amount of donor hair available. Moreover, many individuals electing to undergo this procedure do not progress to transplant surgery as they have insufficient transplantable hair follicles to benefit from the technique as between 2,000 - 5,000 follicles are often needed for this procedure.

The ICX-TRC procedure is significantly less problematic than conventional hair transplants. In terms of the amount of tissue taken from the patient, only a small sample of approximately 120 follicles is needed. As a consequence, trauma suffered by the patient during the procedure may be dramatically reduced. Furthermore, as dermal papilla (DP)cells can be derived from a very small area of hair-bearing scalp, a much higher population of patients will be able to benefit from ICX-TRC than conventional transplantation. Superficial injection of cultured cells into the scalp causes far less tissue damage than implanting multiple hair follicles and is a considerably simpler, shorter and less painful process.

The ICX-TRC procedure

A small sample of hair follicles is taken from the patient during a simple 30 minute operation carried out under local anaesthetic at a hair or skin clinic. The clinic sends the biopsy to Intercytex’ GMP compliant manufacturing facility where the DP cells are dissociated from the rest of the follicle. These cells are cultured and expanded in proprietary media over three weeks and subsequently returned to the clinic in a sterile suspension.

Using a specialised delivery system, the DP cells are microinjected intradermally into the patient’s scalp. The treatment is performed under local anaesthetic and comprises a single procedure of superficial injections, each injection delivering a minute volume of media containing DP cells capable of inducing new hair growth. Following the procedure, new hair growth should become evident after approximately three months.

ICX-TRC clinical and commercial development

Phase I clinical trials (safety) have been completed in seven volunteers at a single UK transplant centre. No safety issues have arisen and five out of seven patients have shown increased hair numbers.

A Phase II clinical efficacy trial on patients with male pattern baldness is being conducted by Dr Bessam Farjo in Manchester, to optimise the delivery of DP cells. In this study, hair counts are obtained by shaving and photographing a small section of scalp, injecting it and then applying a specialised image analysis system to provide total hair count. Two sub-groups of five subjects each were injected with DP cells using different delivery techniques. In the first sub-group, two out of five patients showed substantial increases in hair count at 24 weeks. In the second sub-group, all patients showed substantial and visible increased hair counts at six or twelve weeks. A further eight subjects will be treated with variations in delivery technique. The full data set on all subjects at 24 weeks will be available in during 2008. This detailed analysis will form the basis of further Phase II or Phase III trials as appropriate.

At the end of the trial, photographic data will be analysed from a much larger area of treated scalp on all subject at 12 months.

Manufacturing

Intercytex will manufacture ICX-TRC for Europe and the US from its own manufacturing facilities. In October 2006, Intercytex was awarded a grant from the DTI to develop a robotic system with The Automation Partnership for the commercial scale production of patients’ autologous DP cells. The robotic system has an established track record in processing many different cell samples simultaneously, so that at this scale, in which large numbers of different patients’ cells are handled, all samples remain isolated throughout the multiplication process.

*Source: Coldwater (Market Research)


#4

» What is the latest on hair multiplication?

They should release trial update next month


#5

» What is the latest on hair multiplication?

This from Intercytex’s december press release.

By the end of March 2008 we expect to announce preliminary 12 week data on up to 16 subjects in total and preliminary 24 week data on up to 10 subjects.

so 3 month & 6 month updates…this should give us an idea of the results to expect at different timelines using various techniques.


#6

» What is the latest on hair multiplication?

still a pipe dream


#7

still a pipe dream
and you’re still retarded.

Conservatively speaking, there’s a greater chance we’ll see a cure for MPB in our lifetimes than a cure for your stupidity. Hanging, I’m afraid you’re going to die stupid: either alone and elderly in a ripe pile of your own feces, OR hanging in your outhouse - devastated by the fact HM became reality and you were wrong.

Hanging, you are your own worst enemy. Don’t fight me online; instead, go to the library, read some books, get educated, than come back sounding less like a lame duck.

.


#8

so funny to see how the HM wannabees get so incensed and hurt when anyone dares to doubt their “dream”. after all, they have “hope”

show me one photo proving HM works

show me any HAIR COUNTs of HM showing that it works

Show me that the testing for HM is showing that it is a proven method to regrow hair, or generate new hair …

You WISH AND HOPE that it will someday work, and be affordable, and produce cosmetically acceptable hair, but you really have no idea on earth if this is even possible, much less when.

does HM work? , well no not exactly, it is still in the TESTING phase, there is no definitive verifiable data that one can point to , no end in sight to the testing, no results that can be pointed to that prove anything really

so what is HM now? Still a pipe dream

has anyone ever regrown hair with it? have you ? Is it even viable? Is it approved to be used anywhere in the world? Nope, Nope, Nope

I rest my case

keep dreaming moron :smiley: :smiley:


#9

show me one photo proving HM works
show me one photo proving you’re an adult.

.


#10

» show me one photo proving HM
» works
» show me one photo proving you’re an adult.
»
»
»
» .

funny how when I prove HM is a pipe dream, by challenging it and saying there is nothing to back it up,

instead of bringing out something that disputes my statement,with all your vast knowledge of HM you would think this would be easy to do

but instead

you lay down like a dead dog and basically confirm my assumption, :stuck_out_tongue: :stuck_out_tongue:


#11

We shouldn’t keep fighting with Hangin like this every time he throws a spitball into the discussion. He’s obviously made up his mind on the issue.

I say just let him call HM a “pipe dream” all he wants as long as he’s not purposely spreading misinformation about the facts.


#12

hangin should not be allowed to get hair multi if it is available in next 3 years.


#13

» We shouldn’t keep fighting with Hangin like this every time he throws a
» spitball into the discussion. He’s obviously made up his mind on the
» issue.
»
» I say just let him call HM a “pipe dream” all he wants as long as he’s not
» purposely spreading misinformation about the facts.

the idiot thought ICX was a pharmaceutical comapny a few months ago. why would anybody even try to prove anything to him in the first place?


#14

» » We shouldn’t keep fighting with Hangin like this every time he throws a
» » spitball into the discussion. He’s obviously made up his mind on the
» » issue.
» »
» » I say just let him call HM a “pipe dream” all he wants as long as he’s
» not
» » purposely spreading misinformation about the facts.
»
» the idiot thought ICX was a pharmaceutical comapny a few months ago. why
» would anybody even try to prove anything to him in the first place?

go find the post and post it, …your statement is bs